August 5, 2022
FDA Approves Two Nivolumab-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma BookmarkGeorge Lundberg, MD
The ASCO Post reports on the U.S. Food And Drug Administration (FDA)’s recent approval of two new treatments for advanced, unresectable squamous cell carcinoma of the esophagus.
December 3, 2020
Opdivo Approved in Europe as Second-line Therapy for Advanced Esophageal Cancer BookmarkGeorge Lundberg, MD
Immuno-Oncology News reports on the European Commission’s approval of the drug nivolumab (Opdivo) for some patients with advanced esophageal cancer.